SLC5A2 and Hypoglycemia: The hypothesis put forward in this study is that SGLT-2 inhibitors induce skeletal muscle wasting by increasing the release of amino acids into the systemic circulation as a catabolic response to renal glucose excretion, preventing hypoglycemia.